Related Parties	12 Months Ended
Dec. 31, 2019
Related Parties
Related Parties	Note 16. Related Parties Prior to the Company’s initial public offering, it paid quarterly advisory, monitoring fees and any other related expenses to certain shareholders. The Company had accrued less than $0.1 million and $0.1 million as liabilities, as of December 31, 2019 and December 31, 2018, respectively, and had recognized $0.1 million and $1.1 million of related expense for the years ended December 31, 2019 and 2018, respectively, related to these expenses. Further, the Company leases its Argentina office and warehouse space facilities through a related party lease. The term of the operating lease is through December 31, 2020. For the years ended December 31, 2019 and 2018, the Company incurred rent expense of $0.2 million and $0.2 million, respectively. On August 22, 2018, the Company entered into a Master Service Agreement with United Biosource, LLC or UBC, an Avista portfolio company, for prescription processing and patient access services. In November 2018, the Company and UBC entered into a Statement of Work for services valued at approximately $2.4 million. The Company had accrued less than $0.1 million of liabilities related to this agreement as of December 31, 2019 and had recognized $1.9 million of related expense for the year ended December 31, 2019. There were no accruals or expenses recognized for the year ended December 31, 2018 related to these expenses. In 2016 the Company entered into a two‑year consulting agreement with two Vertical/Trigen shareholders. The term of the agreement requires a compensation rate of $20,833 per month and is a component of the selling, general and administrative expenses. This agreement terminated in January 2018.

Note 16. Related Parties

Prior to the Company’s initial public offering, it paid quarterly advisory, monitoring fees and any other related expenses to certain shareholders. The Company had accrued less than $0.1 million and $0.1 million as liabilities, as of December 31, 2019 and December 31, 2018, respectively, and had recognized $0.1 million and $1.1 million of related expense for the years ended December 31, 2019 and 2018, respectively, related to these expenses. Further, the Company leases its Argentina office and warehouse space facilities through a related party lease. The term of the operating lease is through December 31, 2020. For the years ended December 31, 2019 and 2018, the Company incurred rent expense of $0.2 million and $0.2 million, respectively.

On August 22, 2018, the Company entered into a Master Service Agreement with United Biosource, LLC or UBC, an Avista portfolio company, for prescription processing and patient access services. In November 2018, the Company and UBC entered into a Statement of Work for services valued at approximately $2.4 million. The Company had accrued less than $0.1 million of liabilities related to this agreement as of December 31, 2019 and had recognized $1.9 million of related expense for the year ended December 31, 2019. There were no accruals or expenses recognized for the year ended December 31, 2018 related to these expenses.

In 2016 the Company entered into a two‑year consulting agreement with two Vertical/Trigen shareholders. The term of the agreement requires a compensation rate of $20,833 per month and is a component of the selling, general and administrative expenses. This agreement terminated in January 2018.